Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Gynecologic 8CNS 8Sarcoma 6Gastrointestinal 6Genitourinary 5Thoracic 4Myeloid 3Breast 3Other neoplasm 2Endocrine 2Classical hematology 2Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 2Leukemia 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1Anemia, Refractory 1

Interventions

Cyclophosphamide 261fludarabine phosphate 233Azacitidine 182fludarabine 181Busulfan 176Cytarabine 155Imatinib Mesylate 152Mycophenolic Acid 148Tacrolimus 146Whole-Body Irradiation 142Peripheral Blood Stem Cell Transplantation 140Cyclosporine 110Antilymphocyte Serum 108Melphalan 107Methotrexate 105Filgrastim 101Decitabine 98nilotinib 94venetoclax 79ruxolitinib 79Dasatinib 68Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 63Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
DNA Methylation × Myeloid × Clear all
NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

Phase 1/2 Completed
25 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT00899327 2009-07-08

Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants

National Cancer Institute (NCI)

Unknown
200 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡